Inside PIC/S: Top GMP Deficiencies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside PIC/S: Top GMP Deficiencies
Comparison of the top GMP deficiencies cited by the PIC/S Participating Authorities.


Pharmaceutical Technology
Volume 36, Issue 4, pp. 135-137

Results

Thirty-three out of 39 PIC/S Participating Authorities responded (85%). Seven out of 9 applicants to PIC/S responded (78%). The top most frequently cited categories of GMP deficiencies were:

  • Documentation—manufacturing (24)
  • Design and maintenance of premises (22)
  • Documentation—quality systems (elements / procedures) (20)
  • Personnel issues—training (19)
  • Design and maintenance of equipment (18)
  • Cleaning validation (14)
  • Process validation (14)
  • Product quality review (14)
  • Supplier and contractor audit (13)
  • Calibration of measuring and test equipment(12)
  • Equipment validation (11).

The total number of deficiencies per group of top 10 most frequently cited deficiencies were:

  • Production (99, or 24%)
  • Quality system (82, or 20%)
  • Quality control (59, or 14%)
  • Premises and equipment (58, or 14%)
  • Validation (52, or 12%)
  • Personnel issues (34, or 8%)
  • Materials management (29, or 7%)
  • Regulatory issues (5, or 1%)


Figure 1: Most severe cited GMP deficiencies.
The top most severe GMP deficiencies were (see Figure 1):
  • Design and maintenance of premises (15)
  • Contamination, potential for (chemical, physical, microbial) (12)
  • Design and maintenance of equipment (11)
  • Sterility assurance (9)
  • Batch-release procedures (9)
  • Process validation (9)
  • Cleaning validation (8)
  • Investigation of anomalies (7)
  • Documentation—quality systems (elements/procedures) (7)
  • Regulatory issues—noncompliance with marketing authorization (5)
  • Documentation—manufacturing (5).


Figure 2: Top most severe deficiencies by group.
The total number of deficiencies per group of the top most severe deficiencies were (see Figure 2):
  • Production (44, or 27%)
  • Quality system (32, or 20%)
  • Premises and equipment (28, or 17%)
  • Validation (22, or 14%)
  • Quality control (14, or 9%)
  • Regulatory issues (9, or 6%)
  • Materials management (8, or 5%)
  • Personnel issues (5 or 3%).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here